{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:18:19Z","timestamp":1777540699341,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.mehy.2020.110246","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T11:31:10Z","timestamp":1599132670000},"page":"110246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Can roflumilast become steroid-sparing alternative in the treatment of COVID-19?"],"prefix":"10.1016","volume":"144","author":[{"given":"Chirag A.","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mehy.2020.110246_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105948","article-title":"Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence","volume":"55","author":"Wang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mehy.2020.110246_b0010","doi-asserted-by":"crossref","unstructured":"De Savi C, Hughes DL, Kvaerno L. Quest for a COVID-19 cure by repurposing small-molecule drugs: mechanism of action, clinical development, synthesis at scale, and outlook for supply. Org Process Res Dev 2020; acs.oprd.0c00233. Published 2020 Jun 2. doi:10.1021\/acs.oprd.0c00233.","DOI":"10.1021\/acs.oprd.0c00233"},{"key":"10.1016\/j.mehy.2020.110246_b0015","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https:\/\/www.covid19treatmentguidelines.nih.gov\/. Accessed [24 July, 2020]."},{"key":"10.1016\/j.mehy.2020.110246_b0020","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41577-020-0308-3","article-title":"COVID-19: immunopathology and its implications for therapy","volume":"20","author":"Cao","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.mehy.2020.110246_b0025","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular immune pathogenesis and diagnosis of COVID-19","volume":"10","author":"Li","year":"2020","journal-title":"J Pharm Anal"},{"issue":"1","key":"10.1016\/j.mehy.2020.110246_b0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1479-7364-5-1-30","article-title":"Evolutionary divergence and functions of the human interleukin (IL) gene family","volume":"5","author":"Brocker","year":"2010","journal-title":"Hum Genomics"},{"key":"10.1016\/j.mehy.2020.110246_b0035","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.26078","article-title":"COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients","author":"Chakraborty","year":"2020","journal-title":"J Med Virol"},{"issue":"9","key":"10.1016\/j.mehy.2020.110246_b0040","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","article-title":"An endotoxin-induced serum factor that causes necrosis of tumors","volume":"72","author":"Carswell","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.mehy.2020.110246_b0045","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nri2356","article-title":"Colony-stimulating factors in inflammation and autoimmunity","volume":"8","author":"Hamilton","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"14","key":"10.1016\/j.mehy.2020.110246_b0050","doi-asserted-by":"crossref","first-page":"283","DOI":"10.21037\/atm.2017.06.49","article-title":"Biomarkers for the acute respiratory distress syndrome: how to make the diagnosis more precise","volume":"5","author":"Garc\u00eda-Laorden","year":"2017","journal-title":"Ann Transl Med"},{"issue":"m2648","key":"10.1016\/j.mehy.2020.110246_b0055","article-title":"Dexamethasone in the management of covid -19","volume":"370","author":"Johnson Raymond","year":"2020","journal-title":"BMJ"},{"issue":"m2422","key":"10.1016\/j.mehy.2020.110246_b0060","article-title":"Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds","volume":"369","author":"Elisabeth","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.mehy.2020.110246_b0065","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.2147\/DDDT.S165161","article-title":"Pharmacological mechanism of roflumilast in the treatment of asthma\u2013COPD overlap","volume":"12","author":"Zhang","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"10.1016\/j.mehy.2020.110246_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121725","article-title":"The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation","volume":"10","author":"Konrad","year":"2015","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.mehy.2020.110246_b0075","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pupt.2010.03.011","article-title":"The preclinical pharmacology of roflumilast \u2013 a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease","volume":"23","author":"Hatzelmann","year":"2010","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.mehy.2020.110246_b0080","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1124\/jpet.108.148742","article-title":"Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats","volume":"330","author":"Izikki","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.mehy.2020.110246_b0085","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0022-3565(24)29538-0","article-title":"In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor","volume":"297","author":"Bundschuh","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.mehy.2020.110246_b0090","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2222.2008.02950.x","article-title":"Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma","volume":"38","author":"Herbert","year":"2008","journal-title":"Clin Exp Allergy"},{"issue":"suppl 60","key":"10.1016\/j.mehy.2020.110246_b0095","article-title":"Roflumilast but not dexamethasone or fluticasone reduces neutrophilic airway inflammation and hyperreactivity in a murine influenza-induced asthma exacerbation model","volume":"48","author":"Tilp","year":"2016","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.mehy.2020.110246_b0100","doi-asserted-by":"crossref","first-page":"1700158","DOI":"10.1183\/13993003.00158-2017","article-title":"Effect of roflumilast in patients with severe COPD and a history of hospitalization","volume":"50","author":"Rabe","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.mehy.2020.110246_b0105","unstructured":"F Hu, J Jiang, P Yin. Prediction of potential commercially inhibitors against SARS-CoV-2 by multi-task deep model. arXiv preprint arXiv:2003.00728, 2020."},{"issue":"1","key":"10.1016\/j.mehy.2020.110246_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/idoj.IDOJ_437_18","article-title":"Apremilast in psoriasis and beyond: big hopes on a small molecule","volume":"10","author":"Afra","year":"2019","journal-title":"Indian Dermatol Online J"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720323860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720323860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:34:46Z","timestamp":1759692886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987720323860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":22,"alternative-id":["S0306987720323860"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110246","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can roflumilast become steroid-sparing alternative in the treatment of COVID-19?","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110246"}}